MYGN, Myriad Genetics, Inc.
** On its first quarter fiscal 2012, MYGN posted record revenue of $110.5 million, an increase of 20 percent year over year. Operating income was $41.5 million, an increase of 17 percent from the prior-year period.
MYGN is a leading molecular diagnostic company dedicated to developing and marketing transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess a patient's risk of disease progression and disease recurrence.
More about MYGN at www.myriad.com.
FIRE, Sourcefire, Inc.
** FIRE reported record revenue for third quarter 2011 of $45.2 million, an increase of 25% compared to the same period the prior year, and adjusted net income of $5.7 million, this compares to adjusted net income of $5.2 million in the third quarter of 2010.
With solutions from the network to the endpoint, FIRE provides customers with Agile SecurityTM that is as dynamic as the real world it protects and the attackers against which it defends. Trusted for more than 10 years, FIRE has been consistently recognized for its innovation and industry leadership with dozens of patents, world-class research, and award-winning technology.
More about FIRE at www.sourcefire.com.
FURX, Furiex Pharmaceuticals, Inc.
** FURX reported that it has acquired full exclusive license rights to develop and commercialize the compound MuDelta for the treatment of diarrhea-predominant irritable bowel syndrome (or IBS-D) under its existing development and license agreement with Janssen Pharmaceutica N.V. FURX acquired these rights as a result of Janssen's decision, after an evaluation of strategic fit within its late stage portfolio, not to exercise its option under the agreement to continue development of MuDelta.
FURX also announced today that it held a formal End-of-Phase II meeting with the U.S. Food and Drug Administration, or the FDA, and reached agreement with the FDA on the design of its proposed MuDelta Phase III development plan for IBS-D.
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a functional bowel disorder characterized by chronic abdominal pain and frequent diarrhea, which affects approximately 12 million Americans.
FURX is a drug development collaboration company that uses innovative clinical development design to accelerate and increase value of partnered drug programs by advancing them through the drug discovery and development process in a cost-efficient manner.
More about FURX at www.furiex.com.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyOmega.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyOmega.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://pennyomega.com/disclaimer). Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.